Publications (453) Publications in which a researcher has participated

2025

  1. Human glyoxylate metabolism revisited: New insights pointing to multi-organ involvement with implications for siRNA-based therapies in primary hyperoxaluria

    Journal of Inherited Metabolic Disease, Vol. 48, Núm. 1

2024

  1. Alteraciones del metabolismo del calcio, del fósforo y del magnesio.

    Medicina interna (Elsevier España), pp. 843-851

  2. Biological Activity of 6,7-Dehydroxyroyleanone and Derivatives Obtained from Plectranthus aliciae (Codd) A.J.Paton

    ACS Omega, Vol. 9, Núm. 16, pp. 18113-18118

  3. Cardiovascular health and target end-organ damage and comorbidities in hypertensive patients from a Spanish primary care urban population

    Nefrologia, Vol. 44, Núm. 1, pp. 77-89

  4. Corrigendum to “Renal Disease in Metabolic Syndrome: the Hidden Role of Intrarenal Ischemia” [Kidney International Reports Volume 9, Issue 5, May 2024, Pages 1419-1428](S2468024924014931)(10.1016/j.ekir.2024.02.1403)

    Kidney International Reports

  5. Detection of binucleated nephrin-marked podocytes by flow cytometry in the urine of patients with obesity

    Journal of Nephrology

  6. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

    The Lancet Diabetes and Endocrinology, Vol. 12, Núm. 1, pp. 39-50

  7. Efficacy of the Once-Daily Tacrolimus Formulation LCPT Compared to the Immediate-Release Formulation in Preventing Early Post-Transplant Diabetes in High-Risk Kidney Transplant Patients: A Randomized, Controlled, Open-Label Pilot Study (EUDRACT: 2017-000718-52)

    Journal of Clinical Medicine, Vol. 13, Núm. 24

  8. Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1

    EMBO molecular medicine, Vol. 16, Núm. 1, pp. 112-131

  9. Impact and consequences of the error of estimated GFR in patients with heart failure

    Scientific Reports, Vol. 14, Núm. 1

  10. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

    The Lancet Diabetes and Endocrinology, Vol. 12, Núm. 1, pp. 51-60

  11. Induction of diabetes by Tacrolimus in a phenotypic model of obesity and metabolic syndrome

    Frontiers in Endocrinology, Vol. 15

  12. Inhibition of hepatic oxalate overproduction ameliorates metabolic dysfunction-associated steatohepatitis

    Nature Metabolism, Vol. 6, Núm. 10, pp. 1939-1962

  13. Insights into the pathogenesis of primary hyperoxaluria type I from the structural dynamics of alanine:glyoxylate aminotransferase variants

    FEBS Letters, Vol. 598, Núm. 4, pp. 485-499

  14. Integrated miRNA–mRNA Analysis Reveals Critical miRNAs and Targets in Diet-Induced Obesity-Related Glomerulopathy

    International Journal of Molecular Sciences, Vol. 25, Núm. 12

  15. International consensus on post-transplantation diabetes mellitus

    Nephrology Dialysis Transplantation

  16. Management of heart disease in renal transplant recipients: a national Delphi survey-based SET/SEC/SEN consensus document

    Revista Espanola de Cardiologia

  17. Measured and Estimated Glomerular Filtration Rate to Evaluate Rapid Progression and Changes over Time in Autosomal Polycystic Kidney Disease: Potential Impact on Therapeutic Decision-Making

    International Journal of Molecular Sciences, Vol. 25, Núm. 9

  18. Measured glomerular filtration rate predicts liver related deaths better than estimated glomerular filtration rate in advanced chronic liver disease

    Digestive and Liver Disease

  19. Modulation of the K/BxN arthritis mouse model and the effector functions of human fibroblast-like synoviocytes by liver X receptors

    European Journal of Immunology, Vol. 54, Núm. 11